<p>佛罗里达州科拉尔盖布尔斯，2025 年 12 月 15 日（全球新闻通讯）——Catalyst Pharmaceuticals, Inc.（“Catalyst” 或 “公司”）（纳斯达克：CPRX）是一家商业阶段的生物制药公司，专注于引进、开发和商业化针对罕见和难治疾病患者的新药。今天，Catalyst 的总裁兼首席执行官 Rich Daly 以及其他管理团队成员将于 2026 年 1 月 12 日星期一在第 44 届摩根大通医疗会议上进行演讲。</p>
<p><strong>演讲详情</strong></p>
<p><strong>日期</strong>：2026 年 1 月 12 日星期一</p>
<p><strong>时间</strong>：太平洋标准时间下午 3:45</p>
<p>网络直播链接</p>
<p>网络直播将在公司网站的投资者部分提供，网址为 www.catalystpharma.com，回放将在至少 30 天内提供。</p>
<p><strong>关于 Catalyst Pharmaceuticals, Inc.</strong></p>
<p>Catalyst Pharmaceuticals, Inc.（纳斯达克：CPRX）是一家致力于改善罕见疾病患者生活的生物制药公司。我们拥有将改变生命的治疗方案推向市场的成功记录，专注于引进、商业化和开发创新疗法。我们深切关注患者护理，优先考虑可及性，确保患者通过一整套支持服务获得所需的护理，以提供无缝的访问和持续的帮助。Catalyst 在美国拥有良好的市场基础，这仍然是我们商业战略的基石，同时不断评估战略机会以扩大我们的全球足迹。Catalyst 总部位于佛罗里达州科拉尔盖布尔斯，曾被《福布斯》评选为 2025 年美国最成功的中型公司之一，并在 2025 年德勤技术快速 500™名单中被评为北美增长最快的公司之一。有关更多信息，请访问 Catalyst 的网站 www.catalystpharma.com。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含前瞻性声明，按照 1995 年《私人证券诉讼改革法》的定义。前瞻性声明涉及已知和未知的风险和不确定性，这可能导致 Catalyst 在未来期间的实际结果与预测结果存在重大差异。包括在 Catalyst 的 2024 财年 10-K 表格年报及其后续向美国证券交易委员会（“SEC”）提交的文件中描述的多个因素，可能对 Catalyst 产生不利影响。Catalyst 向 SEC 提交的文件副本可从 SEC 获取，也可在 Catalyst 的网站上找到，或根据请求从 Catalyst 获取。Catalyst 不承担更新此处所含信息的任何义务，该信息仅在此日期有效。</p>
<p>来源：Catalyst Pharmaceuticals, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UZ3hOQ00zTXpJd056TXlJekl3TVRrME9URT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UZ3hOQ00zTXpJd056TXlJekl3TVRrME9URT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTRkZTI0Y2YtZGZhOS00YzE1LWFkNjgtZGQxNDJhNjBiOWFlLTEwMzEwMzEtMjAyNS0xMi0xNS1lbg==/tiny/Catalyst-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTRkZTI0Y2YtZGZhOS00YzE1LWFkNjgtZGQxNDJhNjBiOWFlLTEwMzEwMzEtMjAyNS0xMi0xNS1lbg==/tiny/Catalyst-Pharmaceuticals-Inc-.png"/></p>
<pre><code> 投资者联系：Melissa Kendis，Catalyst Pharmaceuticals, Inc.（305）420-3200 IR@catalystpharma.com 媒体联系：David Schull 或 Olipriya Das，Russo Partners（858）717-2310，（646）942-5588 david.schull@russopartnersllc.com，Olipriya.das@russopartnersllc.com
</code></pre>

触媒制药公司

<p>催化剂制药公司是一家生物制药公司，宣布将参加 2026 年 1 月 12 日举行的第 44 届摩根大通医疗健康大会。公司的总裁兼首席执行官 Rich Daly 以及其他管理层成员将出席并进行演讲。催化剂专注于开发和商业化罕见疾病的治疗方案，并因其增长和成功而受到认可。演讲将通过网络直播，并在公司网站上提供</p>

<p>CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (&#34;Catalyst&#34; or &#34;Company&#34;) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.</p>
<div class="lb-trans"><p>佛罗里达州科拉尔盖布尔斯，2025 年 12 月 15 日（全球新闻通讯）——Catalyst Pharmaceuticals, Inc.（“Catalyst” 或 “公司”）（纳斯达克：CPRX）是一家商业阶段的生物制药公司，专注于引进、开发和商业化针对罕见和难治疾病患者的新药。今天，Catalyst 的总裁兼首席执行官 Rich Daly 以及其他管理团队成员将于 2026 年 1 月 12 日星期一在第 44 届摩根大通医疗会议上进行演讲。</p>
</div><p><strong>Presentation Details</strong></p>
<div class="lb-trans"><p><strong>演讲详情</strong></p>
</div><p><strong>Date</strong>: Monday, January 12, 2026</p>
<div class="lb-trans"><p><strong>日期</strong>：2026 年 1 月 12 日星期一</p>
</div><p><strong>Time</strong>: 3:45pm PST</p>
<div class="lb-trans"><p><strong>时间</strong>：太平洋标准时间下午 3:45</p>
</div><p>Webcast Link</p>
<div class="lb-trans"><p>网络直播链接</p>
</div><p>The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, and a replay will be available for at least 30 days.</p>
<div class="lb-trans"><p>网络直播将在公司网站的投资者部分提供，网址为 www.catalystpharma.com，回放将在至少 30 天内提供。</p>
</div><p><strong>About Catalyst Pharmaceuticals, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Catalyst Pharmaceuticals, Inc.</strong></p>
</div><p>Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst's website at www.catalystpharma.com.</p>
<div class="lb-trans"><p>Catalyst Pharmaceuticals, Inc.（纳斯达克：CPRX）是一家致力于改善罕见疾病患者生活的生物制药公司。我们拥有将改变生命的治疗方案推向市场的成功记录，专注于引进、商业化和开发创新疗法。我们深切关注患者护理，优先考虑可及性，确保患者通过一整套支持服务获得所需的护理，以提供无缝的访问和持续的帮助。Catalyst 在美国拥有良好的市场基础，这仍然是我们商业战略的基石，同时不断评估战略机会以扩大我们的全球足迹。Catalyst 总部位于佛罗里达州科拉尔盖布尔斯，曾被《福布斯》评选为 2025 年美国最成功的中型公司之一，并在 2025 年德勤技术快速 500™名单中被评为北美增长最快的公司之一。有关更多信息，请访问 Catalyst 的网站 www.catalystpharma.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明，按照 1995 年《私人证券诉讼改革法》的定义。前瞻性声明涉及已知和未知的风险和不确定性，这可能导致 Catalyst 在未来期间的实际结果与预测结果存在重大差异。包括在 Catalyst 的 2024 财年 10-K 表格年报及其后续向美国证券交易委员会（“SEC”）提交的文件中描述的多个因素，可能对 Catalyst 产生不利影响。Catalyst 向 SEC 提交的文件副本可从 SEC 获取，也可在 Catalyst 的网站上找到，或根据请求从 Catalyst 获取。Catalyst 不承担更新此处所含信息的任何义务，该信息仅在此日期有效。</p>
</div><p>Source: Catalyst Pharmaceuticals, Inc.</p>
<div class="lb-trans"><p>来源：Catalyst Pharmaceuticals, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01UZ3hOQ00zTXpJd056TXlJekl3TVRrME9URT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMTgxNCM3MzIwNzMyIzIwMTk0OTE="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZTRkZTI0Y2YtZGZhOS00YzE1LWFkNjgtZGQxNDJhNjBiOWFlLTEwMzEwMzEtMjAyNS0xMi0xNS1lbg==/tiny/Catalyst-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZTRkZTI0Y2YtZGZhOS00YzE1LWFkNjgtZGQxNDJhNjBiOWFlLTEwMzEwMzEtMjAyNS0xMi0xNS1lbg==/tiny/Catalyst-Pharmaceuticals-Inc-.png"/></p>
<pre><code>Investor ContactMelissa Kendis, Catalyst Pharmaceuticals, Inc.(305) 420-3200IR@catalystpharma.comMedia ContactDavid Schull or Olipriya Das, Russo Partners(858) 717-2310, (646) 942-5588david.schull@russopartnersllc.com, Olipriya.das@russopartnersllc.com
</code></pre>
<div class="lb-trans"><pre><code> 投资者联系：Melissa Kendis，Catalyst Pharmaceuticals, Inc.（305）420-3200 IR@catalystpharma.com 媒体联系：David Schull 或 Olipriya Das，Russo Partners（858）717-2310，（646）942-5588 david.schull@russopartnersllc.com，Olipriya.das@russopartnersllc.com
</code></pre>
</div>

触媒制药公司将参加第 44 届摩根大通年度医疗健康大会 | CPRX 股票新闻